1. Show article details.

    BRIEF-Harpoon Provides Progress Update For TriTAC Clinical Programs And ProTriTAC Platform

    Reuters – 6:04 PM ET 06/04/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS PROVIDES PROGRESS UPDATE FOR TRITAC® CLINICAL PROGRAMS AND PROTRITAC™ PLATFORM. * HARPOON THERAPEUTICS (HARP) - THREE TRITAC CLINICAL PROGRAMS HAVE SHOWN TUMOR SIZE REDUCTIONS OR STABLE DISEASE, AND MEANINGFUL TREATMENT DURATION.

  2. Show article details.

    Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform

    GlobeNewswire – 4:00 PM ET 06/04/2021

    SOUTH SAN FRANCISCO, Calif., June 04, 2021 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data presented earlier today at ASCO from the ongoing dose escalation portion of the Phase 1/2a trial for HPN424 in patients with metastat...

  3. Show article details.

    BRIEF-Harpoon Therapeutics Presents Updated Interim Clinical Data For The Psma-Targeting Tritac® Hpn424 At The 2021 Asco Annual Meeting

    Reuters – 10:38 AM ET 06/04/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS PRESENTS UPDATED INTERIM CLINICAL DATA FOR THE PSMA-TARGETING TRITAC® HPN424 AT THE 2021 ASCO ANNUAL MEETING Source text for Eikon: Further company coverage:

  4. Show article details.

    Harpoon Therapeutics Presents Updated Interim Clinical Data for the PSMA-targeting TriTAC® HPN424 at the 2021 ASCO Annual Meeting

    GlobeNewswire – 9:00 AM ET 06/04/2021

    SOUTH SAN FRANCISCO, Calif., June 04, 2021 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today presented interim data from the ongoing dose-escalation portion of a Phase 1/2a trial for HPN424 in patients with metastatic castration-resistant prostate cancer at the 2021 American Society of Clinical Oncology Annual Meeting.

  5. Show article details.

    Harpoon Therapeutics to Present Updated Interim Clinical Data for TriTAC® HPN424 at the 2021 ASCO Annual Meeting

    GlobeNewswire – 5:02 PM ET 05/19/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that updated interim Phase 1 data for HPN424 for prostate cancer will be presented at the 2021 American Society of Clinical Oncology Annual Meeting beginning on June 4,2021.

  6. Show article details.

    BRIEF-Harpoon Therapeutics Reports First Quarter 2021 Financial Results And Provides Corporate Update

    Reuters – 5:54 PM ET 05/06/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS REPORTS FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. * Q1 REVENUE $9.0 MILLION. * QTRLY LOSS PER SHARE $1.95 Source text for Eikon: Further company coverage:

  7. Show article details.

    Harpoon Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:04 PM ET 05/06/2021

    Presented encouraging data at the AACR Annual Meeting on potential therapeutic effects of TriTACs and ProTriTACs Appointed experienced biotech leader Alan Colowick, M.D., to board of directors Clinical data updates for all four TriTAC clinical programs expected in 2021 SOUTH SAN FRANCISCO, Calif., May 06, 2021 -- Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a no...

  8. Show article details.

    Harpoon Therapeutics to Participate in Truist Securities Life Sciences Summit

    GlobeNewswire – 4:05 PM ET 04/28/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit.

  9. Show article details.

    BRIEF-Harpoon Therapeutics Says On April 23, Delaware Court Issued Memorandum Opinion

    Reuters – 8:34 AM ET 04/26/2021

    Harpoon Therapeutics Inc (HARP): * HARPOON THERAPEUTICS (HARP) - ON APRIL 23, DELAWARE COURT ISSUED MEMORANDUM OPINION AWARDING MILLENNIUM THERAPEUTICS $38.2 MILLION IN DAMAGES ON CLAIM AGAINST CO. * Harpoon Therapeutics Inc (HARP) - COURT RULED IN FAVOR OF HARPOON ON MAVERICK'S CLAIMS FOR BREACH OF CONTRACT AND MISAPPROPRIATION OF TRADE SECRETS.

  10. Show article details.

    Harpoon Therapeutics Announces Data from Poster Presentations at the AACR Annual Meeting 2021

    GlobeNewswire – 8:30 AM ET 04/10/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the availability of three poster presentations at the American Association for Cancer Research Annual Meeting. Key findings of each of the posters are described below.

  11. Show article details.

    Harpoon Therapeutics Appoints Experienced Biotech Leader Alan Colowick, M.D., to Board of Directors

    GlobeNewswire – 5:09 PM ET 03/24/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced the appointment of Alan Colowick, M.D., to its board of directors. “We are thrilled to welcome Dr. Colowick as the newest member of the Harpoon Board of Directors,” said Ron Hunt, Chairman of the Board of Directors of Harpoon Therapeutics.

  12. Show article details.

    Harpoon Therapeutics Announces Poster Presentations and Publication of Abstracts for AACR Annual Meeting 2021

    GlobeNewswire – 1:16 PM ET 03/11/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced publication of abstracts for three poster presentations at the American Association for Cancer Research Annual Meeting.

  13. Show article details.

    Harpoon Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

    GlobeNewswire – 4:05 PM ET 03/10/2021

    Provided positive update on its four TriTAC® clinical trials, including a confirmed partial response for HPN424 in the treatment of metastatic castration-resistant prostate cancer Nominated first ProTriTAC™ candidate, HPN601 and presented promising preclinical data Clinical data updates for all four clinical programs expected in 2021 Management to host webcast/conference call today, March 10, 2...

  14. Show article details.

    Harpoon Therapeutics to Participate in 33rd Annual Roth Conference

    GlobeNewswire – 7:30 AM ET 03/09/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Jerry McMahon, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 33rd Annual Roth Conference.

  15. Show article details.

    Harpoon Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Corporate Update

    GlobeNewswire – 7:30 AM ET 03/04/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021.

  16. Show article details.

    Harpoon Therapeutics to Participate in SVB Leerink Global Healthcare Conference

    GlobeNewswire – 7:30 AM ET 02/17/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10th Annual Global Healthcare Conference.

  17. Show article details.

    Harpoon Therapeutics Granted Orphan Drug Designation from FDA for HPN217 for Treatment of Multiple Myeloma

    GlobeNewswire – 7:30 AM ET 01/13/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma.

  18. Show article details.

    Harpoon Therapeutics Announces Closing of Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 01/11/2021

    Harpoon Therapeutics, Inc. (HARP) announced today the closing of its underwritten public offering of 6,764,704 shares of its common stock, which includes 882,352 shares sold upon the underwriters’ full exercise of their option to purchase additional shares, resulting in aggregate gross proceeds of approximately $115.0 million, before deducting underwriting discounts and commissions and offering expens...

  19. Show article details.

    Harpoon Therapeutics Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 9:44 PM ET 01/06/2021

    Harpoon Therapeutics, Inc. (HARP), announced today the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17.00 per share.

  20. Show article details.

    Harpoon Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:01 PM ET 01/06/2021

    Harpoon Therapeutics, Inc. (HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, announced today that it has commenced an underwritten public offering of its common stock.

Page:

Today's and Upcoming Events

  • Aug
    03

    HARP to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    06

    HARP announced Q1 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.